Abstract: Provided is a method of treating idiopathic pulmonary fibrosis (IPF) using an agent that reduces or eliminates the kinase activity of checkpoint kinase 1 (Chk1).

Abstract: The present disclosure relates generally to compositions comprising a crosslinked cation-binding polymer comprising monomers containing carboxylic acid groups and pKa decreasing groups, including electron-withdrawing substituents such as halide atoms (e.g., fluorine), and a base, wherein the polymer optionally contains less than about 20,000 ppm of non-hydrogen cations, and wherein the base is present in an amount sufficient to provide from about 0.2 equivalents to about 0.95 equivalents of base per equivalent of carboxylic acid groups in the polymer. The present disclosure also relates to methods of preparation of said compositions and methods of using said compositions to treat various diseases or disorders.

Abstract: The present disclosure relates generally to crosslinked cation-binding polymers comprising monomers containing carboxylic acid groups and pKa decreasing groups, wherein the polymer contains i) calcium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer; or ii) calcium cations and magnesium cations that are counterions to about 5% to about 75% of the carboxylic acid groups in the polymer, wherein the magnesium cations are counterions to no more than about 35% of the carboxylate groups in the polymer. The present disclosure also relates to methods of preparation of the poly mers, and compositions, formulations, and dosage forms containing the polymers, and methods of using the polymers, compositions, formulations, and/or dosage forms to treat various diseases or disorders.